Common Contracts
2 similar null contracts
UPDATE – HTG Molecular Diagnostics and Merck KGaA, Darmstadt, Germany, Enter Into a Master Companion Diagnostics AgreementJuly 8th, 2018
TUCSON, Ariz., Oct. 11, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Merck KGaA, Darmstadt, Germany, have entered a broad companion diagnostics master agreement. The initial development program agreement utilizes the HTG EdgeSeq DLBCL Cell of Origin Assay in the Merck KGaA, Darmstadt, Germany, M7583, selective and irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), program.
HTG Molecular Diagnostics and Merck KGaA, Darmstadt, Germany, Enter Into a Master Companion Diagnostics AgreementJune 25th, 2018
TUCSON, Ariz., Oct. 11, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Merck KGaA, Darmstadt, Germany, have entered a broad companion diagnostics master agreement. The initial development program agreement utilizes the HTG EdgeSeq DLBCL Cell of Origin Assay in the Merck KGaA, Darmstadt, Germany, M7583, selective and irreversible inhibitor of Burton’s Tyrosine Kinase (BTK), program.
